Medindia

X

Dey, L.P. Partners with COPD Foundation in Support of National Heart, Lung and Blood Institute (NHLBI)'s COPD Learn More Breathe Better Awareness Campaign

Thursday, November 29, 2007 General News J E 4
Advertisement
NAPA, Calif., Nov. 28 In recognition of November asNational COPD Awareness Month, Dey, L.P., a subsidiary of Mylan Inc.(NYSE: MYL), has entered into a partnership with the COPD Foundation insupport of the National Heart, Lung and Blood Institute (NHLBI) to raisepublic awareness of Chronic Obstructive Pulmonary Disease (COPD), also knownas emphysema or chronic bronchitis. Through an unrestricted educational grantto the COPD Foundation, Dey, L.P. is supporting the COPD Learn More BreatheBetter campaign, an ongoing initiative to educate the public about COPD andits treatment, and to urge screening and early detection of the disease.

According to the NHLBI's COPD Learn More Breathe Better campaign, COPD isthe fourth leading cause of death in the U.S. after heart disease, cancer, andstroke. Approximately 12 million Americans are being treated for the disease,and it is estimated that at least another 12 million are unaware that theysuffer from COPD. A simple screening test called spirometry can identifythose affected by COPD and enable them to start receiving treatment. The COPDLearn More Breathe Better campaign targets people over the age of 45,particularly current or former smokers or people at risk for a geneticpredisposition to COPD or environmental exposures.

"COPD is a hidden epidemic in this country, and National COPD AwarenessMonth is critically important as an opportunity to combat the public healthcrisis of this disease," said John W. Walsh, President of the COPD Foundationand President and CEO of The Alpha-1 Foundation. "On behalf of the COPDFoundation, I salute Dey, L.P. for becoming the first pharmaceutical companyto provide support for this national public awareness campaign. The company'scommitment to patients and their caregivers is reflected not only in itssupport of the COPD Learn More Breathe Better campaign, but also in its newlycreated educational resource kit for COPD caregivers. The COPD Foundation isdelighted now to be able to offer these unique, free resource kits through ourCOPD Call Center."

"We are proud to join the COPD Foundation in support of the NHLBI's effortto increase public awareness of COPD," said Carolyn Myers, Ph.D., President ofDey, L.P. "As a U.S. leader in nebulized respiratory medications, we have astrong commitment to helping patients understand COPD and receive appropriatetreatment. Through this collaboration with the COPD Foundation in support ofthe NHLBI, Dey will contribute to the campaign's consumer education events aswell as to its distribution of educational materials to physicians and thegeneral public."

Caring for Someone with Emphysema or Chronic Bronchitis, Dey's neweducational resource kit for COPD caregivers, provides disease information, anoverview of various COPD treatment options, and practical lifestyle tips andother suggestions on ways to care for someone living with COPD. Free copiesof this COPD caregiver kit may be requested through the COPD Foundation CallCenter at 1-866-316-COPD.

About COPD

COPD refers to a number of chronic lung disorders in which the airways tothe lungs become narrowed and breathing becomes increasingly difficult. Themost common forms of COPD are chronic bronchitis and emphysema, and manypatients suffer from a combination of the two diseases.

COPD is not well understood or recognized -- most Americans have not heardof it, not even those who may be living with the condition. The most commoncause of COPD is cigarette smoking, which is responsible for an estimated 80to 90 percent of COPD cases. Estimates of the total incidence of COPD inAmerica range from 24 to 30 million.

About Dey, L.P.

Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), is a specialtypharmaceutical company focused on the development, manufacturing and marketingof prescription drug products for the treatment of respiratory diseases,respira
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Boehringer Ingelheim Initiates NEwArT Study Compar...
S
Indevus Pharmaceuticals Reports Positive Results o...